



January 21, 2004

Republic of the Philippines
PHILIPPINE HEALTH INSURANCE CORPORATION

Citystate Centre, 709 Shaw Boulevard, Pasig City
Healthline 637-9999 www.philhealth.gov.ph



PHILHEALTH CIRCULAR

No. 05, s-2004

TO : ALL ACCREDITED HEALTH CARE PROVIDERS, CLAIMS PROCESSING DEPARTMENTS – NATIONAL CAPITAL REGION AND PHILHEALTH REGIONAL OFFICES (PROs), AND ALL OTHERS CONCERNED

SUBJECT : Amendments and clarifications to PhilHealth Circular No. 34 s-2003

Please be guided by the following amendments and clarifications to PhilHealth Circular No. 34 s. 2003 titled Reimbursement of Claims for Drugs Listed in the PNDF Vol. 1 6th Edition and PhilHealth List of Reimbursable Drugs (Positive List):

1. In October 2003, the Department of Health furnished us with the partial list of drugs included in the latest edition of the Philippine National Drug Formulary (PNDF) which is the 6th edition. The annexes of Circular No. 34 provide a summary of the similarities and differences between the 5th edition and 6th edition of the PNDF. The drugs and drug preparations could either be:
 - i. delisted – listed in the 5th edition but removed in the 6th edition,
 - ii. added - not found in the 5th edition but included in the 6th edition, or
 - iii. retained – listed in both the 5th and 6th edition

It is possible though that only a certain drug preparation is delisted or added while the drug per se is retained. Drugs and drug preparations so affected are listed in Annexes 1 and 2 of PhilHealth Circular No. 34 s. 2003.

2. For the tables on Annexes 1 and 2, the first column contains the drugs in their generic/international non-proprietary names (INN); the second column contains the drug's respective routes of administration; and the third column contains the preparations that specify the drug's dosage strength, dosage form and packaging.
3. Section A of Annex 1 contains the drugs, in their generic name, that has been newly included in the 6th edition of the PNDF. These drugs therefore are additional compensable drugs.
4. Section B of Annex 1 contains the newly included **preparations of retained drugs** in the 6th edition of the PNDF. These preparations therefore are additional compensable drug preparations.
5. Section A of Annex 2 contains the drugs, in their generic names, that have been delisted in the 6th edition of the PNDF and are therefore no longer compensable.
6. Section B of Annex 2 contains the **delisted preparations of retained drugs** in the 6th edition of the PNDF. These preparations therefore are no longer compensable. **The retained or newly included preparations of the drugs listed in this section are still compensable.**
7. Further, the following corrections and clarifications on Annexes 1 and 2 are hereby made for your guidance:

"Isang Malusog na Mamamayan. . . . Isang Matatag na Republika!"

ANNEX 1**New Drugs and Drug Preparations Included in the PNDF Vol. 1 6th Edition****A. ADDITIONAL COMPENSABLE DRUGS (by November 1, 2003)****Section 3.0 ANTI-INFECTIVES** (page 1 of Annex 1)

- Didanoside should read as **Didanosine**.

Section 5.0 CARDIOVASCULAR DRUGS (page 1 of Annex 1)

- Add the following drugs, which are already included in the 5th Edition of the PNDF but are classified under a different category. In the latest edition, they are newly listed under Section 5.0 Cardiovascular Drugs.

GENERIC NAME	ROUTE	PREPARATION
<i>Atropine</i>	Inj.:	1mg/ml, 1 ml ampul (IM, IV, SC) (as sulfate)
<i>Enoxaparin</i>	Inj.:	20 mg/0.2 ml, 40 mg/0.4 ml, 60 mg/0.6 ml and 80 mg/0.8 ml pre-filled syringe (SC) ; 100 mg/ml, 1 ml vial (SC)
<i>Unfractionated Heparin</i>	Inj.:	1,000 IU/ml and 5,000 IU/ml, 5 ml vial (IV, IV infusion, SC) (as sodium salt)
<i>Warfarin</i>	Oral:	1 mg, 2.5 mg and 5 mg tablet

B. ADDITIONAL COMPENSABLE DRUG PREPARATIONS (by November 1, 2003)**Section 3.0 ANTI-INFECTIVES** (page 2 of Annex 1)

- **Add** to the list the following **preparation** of Chloroquine:

GENERIC NAME	ROUTE	PREPARATION
<i>Chloroquine</i>	Inj.:	50 mg/ml, 20 ml vial (IM, IV) (as diphosphate)

- **Delete** from the list the following **preparation** of Clindamycin:

GENERIC NAME	ROUTE	PREPARATION
<i>Clindamycin</i>	Inj.:	150 mg/ml, 4 ml vial (IM, IV) (as phosphate)

Section 5.0 CARDIOVASCULAR DRUGS (page 3 of Annex 1)

- Add to the list the following preparation of metoprolol:

GENERIC NAME	ROUTE	PREPARATION
<i>Metoprolol</i>	Oral:	10 mg tablet (as tartrate)

- **Transfer** the drug Enoxaparin to Annex 1.A Section 5.0

GENERIC NAME	ROUTE	PREPARATION
<i>Enoxaparin</i>	Inj.:	100 mg/ml, 1 ml vial (SC)

ANNEX 2

**Drug And Drug Preparations Delisted from the PNDP
(NOT COMPENSABLE BY JANUARY 1, 2004)**

A. DELISTED / NON-COMPENSABLE DRUGS:

- **Delete the date** November 1, 2003 in the subject heading

Section 3.0 ANTI-INFECTIVES (page 1 of Annex 2)

- Please note that in the 5th edition of the PNDP, **Probenecid** is also listed under Section 2.3 Anti-gout.

Section 5.0 CARDIOVASCULAR DRUGS (page 1 of Annex 2)

- **Change preparation** of Dipyridamole 20 mg tablet to:

GENERIC NAME	ROUTE	PREPARATION
<i>Dipyridamole</i>	Oral:	25 mg tablet

- The following should be included in the delisted drugs:

GENERIC NAME	ROUTE	PREPARATION
<i>Phenytoin</i>	Oral:	30 mg and 100 mg capsule (as sodium salt)
		30 mg/5 ml suspension, 120 ml (as sodium salt)
		125 mg/5 ml suspension, 120 ml (as sodium salt)
<i>Quinidine</i>	Inj.:	50 mg/ml, 2 ml ampul (IV) (as sodium salt)
		Oral:

- Please note that in the 5th edition of the PNDP, Phenytoin is also listed under Section 1.3 Anticonvulsants.

B. DELISTED / NON-COMPENSABLE DRUG PREPARATIONS:

- **Delete the date** November 1, 2003 in the subject heading.


Section 3.0 ANTI-INFECTIVES (page 2 of Annex 2)

- **Delete** from the list the following **preparation** of Quinine

GENERIC NAME	ROUTE	PREPARATION
<i>Quinine</i>	Inj.:	300 mg/ml, 1 ml vial (IV) (as dihydrochloride)
		300 mg/ml, 2 ml vial (IV) (as dihydrochloride)

8. We reiterate that the compensability of the drugs depends on their use, which should be as indicated in the 6th edition of the PNDP.

All other provisions of PhilHealth Circular No. 34, s-2003 consistent herewith shall remain in full force and effect.


FRANCISCO T. DUQUE III, MD, MSc
President and CEO